Cantor Fitzgerald downgraded Mainz Biomed to Neutral from Overweight without a price target. The firm cites liquidity and balance sheet concerns and the resulting lack of visibility to the company’s near-term financial performance for the downgrade. Cantor believes Mainz will need $25M of capital next year, which is roughly the size of its current market cap, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
- Mainz Biomed price target lowered to $5 from $9 at H.C. Wainwright
- Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Mainz Biomed reports Q3 EPS (39c), consensus (47c)
- Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering